DUBLIN–(BUSINESS WIRE)–The “Ypsomed Holding AG (YPSN) – Product Pipeline Analysis, 2025 Update” company profile has been added to ResearchAndMarkets.com’s offeringDUBLIN–(BUSINESS WIRE)–The “Ypsomed Holding AG (YPSN) – Product Pipeline Analysis, 2025 Update” company profile has been added to ResearchAndMarkets.com’s offering

Ypsomed Holding AG (YPSN) Product Pipeline Analysis Report 2025: Self-Injection and Infusion Systems Portfolio – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Ypsomed Holding AG (YPSN) – Product Pipeline Analysis, 2025 Update” company profile has been added to ResearchAndMarkets.com’s offering.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

Ypsomed Holding AG (Ypsomed) is a medical device company. It designs, develops, and manufactures injection and infusion systems for self-medication and offers related services. The company’s products find application in the treatment of diabetes, infertility, growth disorders and various other clinical indications. Ypsomed’s product portfolio includes autoinjectors, dual chamber pens, and pen injectors.

The company also provides services ranging from design and development projects, flexible prototyping, human factors engineering, monitoring services, therapy management and IP landscape management to manufacturing and assembly infrastructure and registration support. Ypsomed offers solutions to physicians, and pharmaceutical and biotechnology companies. The company has operations in Switzerland, Europe, and North America, among others. Ypsomed is headquartered in Burgdorf, Switzerland.

The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Report Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Ypsomed Holding AG
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed descriptions of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.

Ypsomed Holding AG, Recent Developments

  • Sep 11, 2025: Ypsomed Receives FDA 510(K) Clearance For SmartPilot YpsoMate NS-A2.25
  • Sep 02, 2025: Sharp Invests $20 Million in Autoinjector & Pen Assembly Lines to Meet Rising Demand for Injectables
  • Sep 01, 2025: Ypsomed Receives FDA Clearance for SmartPilot
  • Jul 01, 2025: Global First Dual GCG/GLP-1 Receptor Agonist for the Treatment of Obesity Launched in an Ypsomed Autoinjector in China
  • Jun 27, 2025: Ypsomed opens production site in China
  • Apr 07, 2025: Ypsomed and Sidekick Health Launch a Collaborative Digital Health Solution for Obesity Management
  • Mar 18, 2025: Ypsomed and CamDiab launch mylife Loop on iOS
  • Nov 13, 2024: Ypsomed significantly increases sales and decides to initiate the sale of Diabetes Care
  • Oct 24, 2024: Ypsomed and BD to Enhance High-Viscosity Drug Delivery
  • Oct 23, 2024: Ypsomed and BD collaborate to advance self-injection systems for high viscosity biologics

Key Topics Covered:

  • Ypsomed Holding AG Company Overview
  • Ypsomed Holding AG Company Snapshot
  • Ypsomed Holding AG Pipeline Products and Ongoing Clinical Trials Overview
  • Ypsomed Holding AG – Pipeline Analysis Overview
  • Business Description
  • Ypsomed Holding AG – Key Facts
  • Ypsomed Holding AG – Major Products and Services
  • Ypsomed Holding AG Pipeline Products by Development Stage
  • Ypsomed Holding AG Ongoing Clinical Trials by Trial Status
  • Ypsomed Holding AG Pipeline Products Overview
  • mylife Loop
  • mylife Loop Product Overview
  • mylife Loop Clinical Trial
  • mylife YpsoPump
  • mylife YpsoPump Product Overview
  • mylife YpsoPump Clinical Trial
  • mylife YpsoPump 2.0 With Integrated CGM
  • mylife YpsoPump 2.0 With Integrated CGM Product Overview
  • UnoPen Zero
  • UnoPen Zero Product Overview
  • YpsoDose
  • YpsoDose Product Overview
  • YpsoDose Zero
  • YpsoDose Zero Product Overview
  • YpsoMate Zero 2.25 Pro
  • YpsoMate Zero 2.25 Pro Product Overview
  • YpsoMate Zero On
  • YpsoMate Zero On Product Overview
  • YpsoPod
  • YpsoPod Product Overview
  • Ypsomed Holding AG – Key Competitors
  • Ypsomed Holding AG – Key Employees
  • Ypsomed Holding AG – Key Employee Biographies
  • Ypsomed Holding AG – Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Recent Developments
  • Appendix

For more information about this company profile visit https://www.researchandmarkets.com/r/43pquj

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Market Opportunity
Major Logo
Major Price(MAJOR)
$0.12228
$0.12228$0.12228
-0.97%
USD
Major (MAJOR) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Ethereum unveils roadmap focusing on scaling, interoperability, and security at Japan Dev Conference

Ethereum unveils roadmap focusing on scaling, interoperability, and security at Japan Dev Conference

The post Ethereum unveils roadmap focusing on scaling, interoperability, and security at Japan Dev Conference appeared on BitcoinEthereumNews.com. Key Takeaways Ethereum’s new roadmap was presented by Vitalik Buterin at the Japan Dev Conference. Short-term priorities include Layer 1 scaling and raising gas limits to enhance transaction throughput. Vitalik Buterin presented Ethereum’s development roadmap at the Japan Dev Conference today, outlining the blockchain platform’s priorities across multiple timeframes. The short-term goals focus on scaling solutions and increasing Layer 1 gas limits to improve transaction capacity. Mid-term objectives target enhanced cross-Layer 2 interoperability and faster network responsiveness to create a more seamless user experience across different scaling solutions. The long-term vision emphasizes building a secure, simple, quantum-resistant, and formally verified minimalist Ethereum network. This approach aims to future-proof the platform against emerging technological threats while maintaining its core functionality. The roadmap presentation comes as Ethereum continues to compete with other blockchain platforms for market share in the smart contract and decentralized application space. Source: https://cryptobriefing.com/ethereum-roadmap-scaling-interoperability-security-japan/
Share
BitcoinEthereumNews2025/09/18 00:25
AVAX token reclaims top 20 spot after USDC supply expansion

AVAX token reclaims top 20 spot after USDC supply expansion

The post AVAX token reclaims top 20 spot after USDC supply expansion appeared on BitcoinEthereumNews.com. Avalanche’s native token AVAX responded to the latest news of the network’s growth, rallying to a three-month peak above $35 as it repositioned itself for DeFi.  Trading volumes also rose to the highest level in three months, at $2.12B. AVAX also went through a short squeeze, liquidating short positions above $35.  The latest rally also surprised Hyperliquid whales, who were betting on a price slide. A total of 17 whales hold small gains or unrealized losses, while only 11 whales are long on AVAX. For now, the token seems to have finished the short liquidations, and a downturn is possible to attack liquidity accrued for long positions at around $33. AVAX open interest is also close to its peak, at $924M, with over 73% of traders picking a long position. The token is one of the relatively old assets from the 2021 bull market, which is still reinventing its network and DeFi capabilities.  AVAX continued its expansion after the recent plans to launch a $1B treasury based on discounted tokens from the Avalanche Foundation. Additionally, the chain saw increased activity, with over 78K daily active addresses. AVAX rallies on rapid USDC inflows USDC on AVAX is the most rapidly expanding stablecoin version, based on Token Terminal data. For the past month, the chain expanded its supply by 65.9%, for a total of over $1.2B in USDC.  In total, Avalanche carries over $2.4B in various stablecoins, with a total value locked of $2.26B.  One of the chief drivers of expansion is the chain’s version of Aave, which grew its value locked by over 33% in the past month.  Recently, Aave C-Chain also entered the top 5 of networks with the biggest inflows, with a net $6.3M added in the past 24 hours. C-Chain was surpassed by BNB Smart Chain, just behind Ethereum and…
Share
BitcoinEthereumNews2025/09/19 21:58
Neo Foundation Co-Founders Dispute Over Treasury Control

Neo Foundation Co-Founders Dispute Over Treasury Control

Neo co-founders Erik Zhang and Da Hongfei dispute treasury control, with operational continuity affirmed.
Share
coinlineup2026/01/01 06:58